Medical Developments International Limited (MVP) Earnings Dates, Call Summary & Reports

Q: When does Medical Developments International Limited (AU:MVP) report earnings?

Medical Developments International Limited (AU:MVP) is schdueled to report earning on Aug 20, 2026, TBA (Confirmed).

Q: What is Medical Developments International Limited (AU:MVP) earnings time?

Medical Developments International Limited (AU:MVP) earnings time is at Aug 20, 2026, TBA (Confirmed).

Q: Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

Q: What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

Q: What is the P/E ratio of Medical Developments International Limited stock?

The P/E ratio of {name} is N/A.

Q: What is AU:MVP EPS forecast?

AU:MVP EPS forecast for the fiscal quarter 2026 (Q4) is >-0.01.

Compare

10 Followers

Earnings Data

Report Date

Aug 20, 2026

TBA (Confirmed)

Period Ending

2026 (Q4)

Consensus EPS Forecast

>-0.01

Last Year’s EPS

>-0.01

Same Quarter Last Year

Analyst Consensus

Moderate Buy

Based on 1 Analysts Ratings

Earnings Call Summary

Q2 2026

Earnings Call Date:Feb 18, 2026|

% Change Since:

Earnings Call Sentiment|Neutral

The call presented a mix of positive operational progress and near-term headwinds. Highlights include 8% group revenue growth, strong Pain Management momentum (+18%), positive operating cash flow, published pediatric data and imminent Europe pediatric approvals, pricing actions expected to add ~A$1m margin, and early partner traction (France +10%). Offsetting these are meaningful Respiratory weakness driven by a 16% U.S. decline and overall segment -10%, a ~$1.1m FX drag, short-term earnings impact from partner transitions (~$600k) and higher medical/commercial spending (~$500k), plus U.S. tariff uncertainty and market valuation concerns. On balance the company shows clear strategic progress and improved underlying performance when adjusted for FX, but near-term respiratory softness and transition-related impacts temper the outlook.

Company Guidance

The company guided that it expects to finalize pediatric approvals in Europe (device approval received; remaining country‑level medicines approvals—including the important U.K. market—targeted by August) and to support the subsequent label launch while continuing targeted medical/commercial investment and real‑world evidence generation (including a health‑economic study due by end FY‑26); financially it cautioned that seasonally softer Respiratory demand (U.S. respiratory sales -16% H1; overall Respiratory down 10% H1) is expected to persist and drive second‑half earnings lower than H1, even as Pain Management momentum (group revenue +8% H1; Pain +18% H1; Europe underlying demand +10%—U.K./Ireland +8%, France +10%, Nordics +16%; Australia Pain revenue +18%, volumes +9%, hospital +26%) supports growth; management reiterated margin focus with an expected ~A$1.0m FY‑26 margin uplift from Australian pricing (H1 benefits included +A$700k from higher Penthrox pricing and ~A$1.0m net earnings benefit from higher volumes/pricing, partly offset by A$600k transition costs and A$500k higher spend, and A$1.1m FX headwinds), reported positive operating cash flow of A$300k (A$1.0m improvement YoY) and A$16.9m cash balance to fund the plan.

Group Revenue Growth

Group revenue increased 8% in FY '26 H1 versus prior period, reflecting stronger underlying performance.

Pain Management Outperformance

Pain Management revenue rose 18% driven by higher Penthrox volumes and improved pricing in Australia.

Regional Volume Gains

Penthrox volumes grew across all regions: Europe underlying demand +10% (U.K. & Ireland +8%, France +10%, Nordic +16%), Australia volume +9% (hospital segment +26%), and Rest of World markets showing strong growth.

Positive Operating Cash Flow and Strong Balance Sheet

Operating cash flow was positive at $300,000, an improvement of $1.0m versus prior year; cash at period end was $16.9m, and free cash flow improved with slightly lower CapEx.

Pediatric Label Progress and MAGPIE Publication

MAGPIE pediatric study published; nearing final approvals for pediatric indication (age 6+) in Europe with device approval received and expectation of country-level approvals by August, broadening addressable market and enabling ambulance trust adoption.

Evidence Generation and Health Economics Work

Completed a health economic study showing ED cost and operational savings for Penthrox (publication expected by end FY '26) and supporting multiple real-world evidence studies to aid adoption.

Commercial and Regulatory Momentum

Increased on‑the‑ground commercial and medical efforts, extension of PBS prescriber eligibility to nurse practitioners in Australia, and partners (Ethypharm, Labatec) mobilized to expand market access.

Pricing Actions Supporting Margins

July pricing increases in Australia moved remaining ~25% of Australian volume to new prices (aligned with PBS), expected to deliver ~A$1m margin improvement in FY '26.

Early Partner Success in France

After Ethypharm field deployment, France volumes were reported up ~10% versus prior corresponding period, indicating early traction under partner-based supply.

Underlying Earnings Improvement (Ex-FX)

Excluding foreign exchange movements, underlying EBIT and NPAT improved by approximately $0.5m in the period, indicating operational progress after adjusting for FX noise.

Medical Developments International Limited (AU:MVP) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

AU:MVP Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 20, 2026	2026 (Q4)	>-0.01 / -	-0.002	―	―	―
Feb 18, 2026	2026 (Q2)	-0.01 / >-0.01	0.003	-166.67% (>-0.01)		―
Aug 20, 2025	2025 (Q4)	-0.01 / >-0.01	-0.348	99.43% (+0.35)	―	―
Feb 19, 2025	2025 (Q2)	-0.02 / <0.01	-0.124	102.42% (+0.13)	―	―
Aug 25, 2024	2024 (Q4)	-0.20 / -0.35	-0.1	-248.00% (-0.25)	―	―
Feb 28, 2024	2024 (Q2)	-0.04 / -0.12	0.029	-527.59% (-0.15)	―	―
Aug 30, 2023	2023 (Q4)	- / -0.10	-0.068	-47.06% (-0.03)	―	―
Feb 23, 2023	2023 (Q2)	- / 0.03	-0.099	129.29% (+0.13)	―	―
Aug 25, 2022	2022 (Q4)	- / -0.07	-0.05	-36.00% (-0.02)	―	―
Feb 24, 2022	2022 (Q2)	- / -0.10	-0.017	-482.35% (-0.08)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

AU:MVP Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Feb 18, 2026	AU$0.46	AU$0.46	0.00%
Aug 20, 2025	AU$0.64	AU$0.62	-3.13%
Feb 19, 2025	AU$0.76	AU$0.84	+10.53%
Feb 28, 2024	AU$0.85	AU$0.87	+2.35%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Medical Developments International Limited (AU:MVP) report earnings?

Medical Developments International Limited (AU:MVP) is schdueled to report earning on Aug 20, 2026, TBA (Confirmed).

What is Medical Developments International Limited (AU:MVP) earnings time?

Medical Developments International Limited (AU:MVP) earnings time is at Aug 20, 2026, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of Medical Developments International Limited stock?

The P/E ratio of Medical Developments International Limited is N/A.

What is AU:MVP EPS forecast?

AU:MVP EPS forecast for the fiscal quarter 2026 (Q4) is >-0.01.